Cancer-Glargine Data Inconclusive, Groups Agree: Patients urged not to change insulins.

ATLANTA — Reaction by medical societies and the Food and Drug Administration to articles published last month suggesting a link between insulin glargine and cancer has been swift and unified: Patients with diabetes who are using glargine should not change their insulin regimen, because there is no clear evidence of such a relation.